The latest update is out from Shattuck Labs (STTK).
Shattuck Labs, Inc. has shared encouraging preliminary results from its Phase 1B clinical trial, which is evaluating SL-172154 combined with azacitidine in treating patients with high-risk myelodysplastic syndromes and TP53 mutant acute myeloid leukemia. This news, potentially significant for investors and those tracking advancements in cancer therapies, highlights the progress Shattuck Labs is making in its oncology pipeline.
For an in-depth examination of STTK stock, go to TipRanks’ Stock Analysis page.
